Atherosclerotic plaque burden reduction in Native and Intervened coronary arteries as well as in other Major arteries by High Dose ATorvastatin ThErapy-A double blind, randomized study (ANIMATE)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000649

Enrollment

Unknown

Registered

2005-09-09

Start date

2003-07-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart and Blood Vessel Diseases

Interventions

Two groups:Atorvastatin 10 mg or 80 mg daily, 6 months

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: *Patient with established CAD indicated for PCI *Plasma LDL-cholesterol level >2.6mmol/L or clinically indicated for statin therapy

Exclusion criteria

Exclusion criteria: Exclusion criteria: *Significant renal failure that preclude coronary angiography and PCI *Significant left main CAD with significant risk to IVUS *Less than 6 months survival

Design outcomes

Primary

Measure	Time frame
1. Atherosclerotic plaque burden by IVUS in the diseased native coronary artery that does not require PC1; 2. Atherosclerotic plaque burden by IVUS and restenosis by both IVUS and QCA for the degree of neointimal hyperplasia in the post-PCI coronary artery; 3. Neointimal thickness of the carotid and brachial artery; 4. Brachial artery dilatation in response to hyperaemia, i.e. the flow-depend dilatation as an indicator of endotheial function; 5. only apply to the IVUS arm;	—

Measure

Time frame

1. Atherosclerotic plaque burden by IVUS in the diseased native coronary artery that does not require PC1; 2. Atherosclerotic plaque burden by IVUS and restenosis by both IVUS and QCA for the degree of neointimal hyperplasia in the post-PCI coronary artery; 3. Neointimal thickness of the carotid and brachial artery; 4. Brachial artery dilatation in response to hyperaemia, i.e. the flow-depend dilatation as an indicator of endotheial function; 5. only apply to the IVUS arm;

—

Secondary

Measure	Time frame
1. Coronary diameter and percentage stenosis by QCA; 2. Cardiovascular event rate; 3. Correlation of the degree of atherosclerotic plaque regression to symptoms and cardiovascular event rate;	—

Countries

China

Contacts

Public ContactProf Cheuk Man Yu

www.na@163.com+852 2632 3136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026